Angiogenesis-related factor

"Angiogenesis-related factors" is not a single molecule or receptor but rather an umbrella term encompassing numerous proteins and signaling molecules that regulate the process of new blood vessel formation from pre-existing vasculature. These include pro-angiogenic growth factors such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), angiopoietins, and others that stimulate endothelial cell proliferation, migration, survival, and organization into new vessels. Conversely, anti-angiogenic proteins like thrombospondin and endostatin inhibit these processes to maintain vascular homeostasis. The balance between these opposing signals determines whether angiogenesis occurs in physiological contexts like wound healing or pathological settings such as cancer progression. Because "angiogenesis-related factors" refers to a diverse set of molecules with different structures and functions—including receptors (e.g., VEGFR2), transcriptional regulators (e.g., HIF1α), enzymes involved in matrix remodeling—and not one defined therapeutic target or protein family member with a unique sequence or structure,[1][2][4] it cannot be considered a canonical drug target itself. Therefore: This entry is incorrect for use as an individual therapeutic target—it should be replaced by more precise terms referring to specific pro-/anti-angiogenic proteins such as "Vascular endothelial growth factor A," "VEGF receptor 2," etc.[1][3]

Other names

Pro-angiogenic factorAnti-angiogenic factorAngiogenic growth factorAngiogenesis regulatorVascular growth factor (context-dependent)